what is the big difference between the two

On the internet and also in the medical and scientific community, injectable pens of type 2 diabetes treatment still raises doubts among part of the Brazilian population. Despite having similar effects, Ozempic, from the pharmaceutical company Novo Nordisk, and Mounjaro, from Eli Lilly, have different assets and actions.

In common, in addition to treating diabetes, they also have the effect of prolonging satiety, with consequent weight loss. However, the medicines are approved by Anvisa only for the purpose of treating people with diabetes type 2. In addition, they need medical monitoring.

Semaglutide and tizerpatide

O Ozempic Its active ingredient is semaglutide, a substance that simulates the hormone GLP-1 (glucagon-like peptide 1).

In general, it is already produced naturally by the intestine, and is released when there is sugar in the blood, in order to stimulate the pancreas to produce insulin for the cells to absorb the glucose. This is what happens after meals, for example.

Meanwhile, Mounjaro has at its base the tirzepatide. In addition to also simulating the hormone GLP-1, it acts like another hormone, GIP (gastric inhibitory peptide). Therefore, the medicine is known for being a double agonist, that is, it imitates the action of two hormones.

In general, GIP and GLP-1 interact positively, which enhances the insulin production effect and, therefore, glucose absorption. Thus, the medicine prevents spikes in blood sugar.

Therefore, both Ozempic and Mounjaro They are indicated for the treatment of type 2 diabetes, a chronic disease that causes people to have problems carrying out this process naturally.

Although both medications are very effective, as they act as a double agonist, Mounjaro presents more “potent” results, according to clinical studies carried out with tizerpatide in different dosages and with participants from several countries, including Brazil.

Approximately 51% of patients who used Mounjaro 15 mg achieved blood glucose levels below 5.7%, a level found in people without diabetes. Meanwhile, among those who used Ozempiconly 20% achieved such good results.

About using Mounjaro and Ozempic

Both medications received Anvisa approval (National Health Surveillance Agency) as a treatment for type 2 diabetes. Although they are already sold in other countries, such as the USA, only Ozempic has already arrived in Brazil.

For now, Mounjaro does not yet have a date to arrive in Brazilian pharmacies. There is also no forecast of a sales value for the medicine.